Revenue Recognition - Schedule of net revenue from collaborative arrangements (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue Recognition and Collaboration Arrangements
Total net royalty revenue	$ 80,992	$ 108,220	$ 157,364	$ 198,279
Royalty revenue
Revenue Recognition and Collaboration Arrangements
Total net royalty revenue	62,265	108,220	119,123	198,279
GSK
Revenue Recognition and Collaboration Arrangements
Total net royalty revenue	62,265	108,220	119,123	198,279
GSK | Royalty revenue
Revenue Recognition and Collaboration Arrangements
Royalties	65,721	111,676	126,035	205,191
Less: amortization of capitalized fees paid to a related party	(3,456)	(3,456)	(6,912)	(6,912)
GSK | RELVAR/BREO
Revenue Recognition and Collaboration Arrangements
Royalties	54,454	59,326	105,337	115,090
GSK | ANORO
Revenue Recognition and Collaboration Arrangements
Royalties	11,267	9,630	20,698	18,072
GSK | TRELEGY
Revenue Recognition and Collaboration Arrangements
Royalties	$ 0	$ 42,720	$ 0	$ 72,029